NPS Pharmaceuticals, Inc. (NPSP)
-NasdaqGM 14.86 
0.39(2.56%) 11:43AM EDT - Nasdaq Real Time Price
| Prev Close: | 15.25 |
|---|
| Open: | 15.05 |
|---|
| Bid: | 14.83 x 800 |
|---|
| Ask: | 14.84 x 700 |
|---|
| 1y Target Est: | 18.83 |
|---|
| Beta: | 0.63 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 14.71 - 15.22 |
|---|
| 52wk Range: | 6.62 - 16.37 |
|---|
| Volume: | 617,093 |
|---|
| Avg Vol (3m): | 2,051,390 |
|---|
| Market Cap: | 1.40B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.19 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NPS Pharmaceuticals Issues New Stockat Motley Fool(Thu, May 23)
- NPS Pharma Prices OfferingZacks(Thu, May 23)
- Land NPSP Even Lower Than Its Secondary?at Forbes(Thu, May 23)
- NPS Pharmaceuticals Honored For FDA Gattex Approval and 2 More Heavily Traded Stocks to Followat Wall St. Cheat Sheet(Wed, May 22)
- NPS Pharmaceuticals to Present at Deutsche Bank Health Care ConferenceBusiness Wire(Wed, May 22)
- NPS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhiEDGAR Online(Wed, May 22)
- NPS Pharmaceuticals Prices Public Offering of Common StockBusiness Wire(Tue, May 21)
- NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of its Common StockBusiness Wire(Mon, May 20)
- NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized as Regional Finalist for Ernst & Young Entrepreneur of the Year® 2013Business Wire(Thu, May 16)
- NPS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Wed, May 15)
- NPS Pharmaceuticals Recognized by National Organization for Rare Disorders for Gattex® as an Innovative Treatment for Patients with Short Bowel SyndromeBusiness Wire(Wed, May 15)
- NPS Pharmaceuticals Inc Stock Upgraded (NPSP)at TheStreet(Tue, May 14)
- 3 Healthcare Stock Winners and 1 Loser After Earnings Are Digestedat Wall St. Cheat Sheet(Sun, May 12)
- NPS Pharma rises on early sales of bowel drugAP(Thu, May 9)
- Why NPS Pharmaceuticals Is Up After Earningsat Motley Fool(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | 37.08 |
|---|
| P/S (ttm): | 13.27 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.18 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -2.33 |
|---|
Business Summary
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on pa...
View More